# Assess the Safety and Efficacy of Convalescent Plasma to Limit COVID-19 Associated Complications

> **NCT04374487** · PHASE2 · UNKNOWN · sponsor: **Max Healthcare Insititute Limited** · enrollment: 100 (actual)

## Conditions studied

- COVID 19

## Interventions

- **DRUG:** Convalescent Plasma
- **OTHER:** Standard Care Therapy

## Key facts

- **NCT ID:** NCT04374487
- **Lead sponsor:** Max Healthcare Insititute Limited
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-05-09
- **Primary completion:** 2021-08-09
- **Final completion:** 2021-08-09
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2020-07-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04374487

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04374487, "Assess the Safety and Efficacy of Convalescent Plasma to Limit COVID-19 Associated Complications". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04374487. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*